Özet:

Objective: It was aimed to compare neuropathic pain with other risk factors in patients with type 2 diabetes mellitus using long-term oral antidiabetic and insulin. Materials and Methods: According to the American Diabetes Society criteria, 100 patients with Type 2 diabetes mellitus were included in the study. Patients underwent neurological examination, Leeds Assessment of Neuropatic Symptoms and Signs (LANSS) and McGill Melzack Pain Questionnaire Form were applied. Patients were divided into two groups as Neuropathic Pain group (LANSS ≥12) and Non-Neuropathic Pain group (LANSS <12). Groups were compared in terms of demographic characteristics, duration of diabetes, antidiabetic therapy, serum glucose and HbA1c values, presence of hyperlipidemia and hypertension. Results: Neuropathic pain was detected in 51% of the patients. Advanced age, long diabetes duration, high serum glucose and HbA1c levels, presence of hypertension in the Neuropathic Pain group, compared with the Non-Neuropathic Pain group significant difference was found. (P<0.05) There was no significant difference between the groups in terms of gender, presence of hyperlipidemia, and antidiabetic therapy. (P> 0.05) Neuropathic pain localization was most commonly distal to the lower and upper extremities, pattern was paroxysmal and spontaneous, the most commonly used phrases in the definition was 'warmth', 'thorn bumps' and the most common trigger was anxiety. Conclusion: In the development of neuropathic pain with type 2 diabetes mellitus; advanced age, long diabetes duration, poor glycemic control and presence of hypertension play an important role. Gender, presence of hyperlipidemia, and antidiabetic therapy don't make difference in the development of neuropathic pain.

Anahtar Kelimeler: